Analysis of arrhythmias in the Circadian antiischemia program in Europe (CAPE) study

Journal of Cardiovascular Pharmacology

Volumn 33, Issue 1, 1999, Pages 135-139

  Lichtlen, Paul R ^a,c   Fisher, Lloyd D ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NONE   (Switzerland)

Author keywords

Blocker; Amlodipine; Arrhythmia; CAPE; Coronary artery disease

Indexed keywords

AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; NITRIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; HEART ARRHYTHMIA; HOLTER MONITORING; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; AMLODIPINE; ARRHYTHMIA; CALCIUM CHANNEL BLOCKERS; CORONARY DISEASE; DOUBLE-BLIND METHOD; EUROPE; HUMANS; MIDDLE AGED; PROGRAM EVALUATION; TREATMENT OUTCOME;

EID: 0032924855     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199901000-00020     Document Type: Article

References (21)

1. Parmley WW, Nesto RW, Singh BN, Deanfield J, Gottlieb SO, the N-CAP group. Attenuation of the circadian patterns of myocardial ischemia with nifedipine GITS in patients with chronic stable angina. J Am Coll Cardiol 1992;19:1390-9.
2. Balasubramanian V, Bowles MJ, Khumpl NS, et al. Comparative effectiveness of verapamil and nifedipine in stable angina pectoris. Am J Cardiol 1982;50:1173.
3. Opie LH, Messerli FH. Nifedipine and mortality: grave effects in the dossier [Editorial]. Circulation 1995;92:1074-8.
4. Deanfield JE, Detry JMRG, Lichtlen PR, Magnani B, Sellier E. Amlodipine reduces transient myocardial ischemia in patients with coronary artery disease: double-blind Circadian Anti-ischemia Program in Europe (CAPE trial). J Am Coll Cardiol 1994;24:1460-7.
5. Furberg CD, Psaty NBM, Meyer JV. Nifedipine, dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-31.
6. Ruzicka M, Leenen FHH. Relevance of intermittent increases in sympathetic activity for adverse outcome on short-acting CA antagonists. In: Laragh JH, Bremer DM, eds. Hypertension: pathophysiology, diagnosis and management. New York: Raven Press, 1995:2815-25.
7. Egstrup K, Anderson PE. Transient myocardial ischemia during nifedipine therapy in stable angina pectoris, and its relation to coronary collateral flow and comparison with metoprolol. Am J Cardiol 1993;71:177-83.
8. Cheng CP, Noda T, Norländer M, Ohno M, Little WA. Comparison of effects of dihydropyridine Ca antagonists on left ventricular systolic and diastolic performance. J Pharmacol Exp Ther 1994;268:1232-41.
9. Burges RA. Review of the pharmacology of amlodipine. J Cardiovasc Pharmacol 1992;20(suppl A):S1-5.
10. Opie LH. Clinical use of Ca channel antagonist drugs. In: Nifedipine, side effects. 2nd ed. Boston: Kluwer Academic Publishers, 19xx:197.
11. Rehnquist N, Olsson G, Erhardt L, et al. Metoprolol during acute myocardial infarction reduces ventricular arrhythmias both in the early stage and after acute event. Int J Cardiol 1987;15:301-8.
12. Rehnquist N, Hjemdahl P, Billing E, et al. Effects of metoprolol versus verapamil in patients with stable angina pectoris: the Angina Prognosis Study in Stockholm (APSIS). Eur Heart J 1996;17:76-81.
13. Echt DS, Liebson PhR, Mitchell LB, et al., and the CAST investigators. Mortality and morbidity in patients receiving encainide, flecainide or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-8.
14. Cardiac Arrhythmia Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-12.
15. Cohn PF, Vetrovec GW, Nesto R, Gerber FR, and the Total Ischemia Awareness Program Investigators. The Nifedipine Total Ischemia Awareness Program: a national survey of painful and painless myocardial ischemia including results of anti-ischemia therapy. Am J Cardiol 1989;63:534-9.
16. Frishman W, Charlap S, Kimmel B, et al. Diltiazem, nifedipine, and their combination in patients with stable angina pectoris: effects of angina, exercise tolerance, and the ambulatory electrocardiographic ST-segment. Circulation 1988;77:774-86.
17. Mulcahy D, Keegan J, Cunningham D, et al. Circadian variation in total ischemic burden and its alteration with anti-anginal agents. Lancet 1988;2:755-9.
18. Perrot B, Danchin N, Terrier de la Chaise A. Verapamil: a cause of sudden death in a patient with hypertrophic cardiomyopathy. Br Heart J 1984;51:352-1.
19. Buss J, Lassere JJ, Heene DL. Asystole and cardiogenic shock due to combined treatment with verapamil and flecainide. Lancet 1992;340:546.
20. Abascal VM, Larson MG, Evans JC, Poli KA, Levy D. Ca channel blocker use is not associated with increased mortality. Circulation 1996;8:I-578A.
21. Ueda S, Meredith PA, Howie CA, Elliott HL. A comparative assessment of the duration of action of amlodipine and nifedipine GITS in normotensive subjects. Br J Clin Pharmacol 1993;36:561-6.